1: De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother. 2013 Jan 23;23(3):93-101. doi: 10.3851/IMP2533. Review. PubMed PMID: 23343513.
2: Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011 Jun;55(6):2847-54. doi: 10.1128/AAC.01446-10. PubMed PMID: 21444712; PubMed Central PMCID: PMC3101458.
3: Derudas M, Quintiliani M, Brancale A, Andrei G, Snoeck R, Balzarini J, McGuigan C. Evaluation of novel phosphoramidate ProTides of the 2'-fluoro derivatives of a potent anti-varicella zoster virus bicyclic nucleoside analogue. Antivir Chem Chemother. 2010 Oct 28;21(1):15-31. doi: 10.3851/IMP1661. PubMed PMID: 21045257.
4: McGuigan C, Derudas M, Quintiliani M, Andrei G, Snoeck R, Henson G, Balzarini J. 2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6264-7. doi: 10.1016/j.bmcl.2009.09.116. PubMed PMID: 19833513.
5: McGuigan C, Balzarini J. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. J Antimicrob Chemother. 2009 Oct;64(4):671-3. doi: 10.1093/jac/dkp294. Review. PubMed PMID: 19679595.
6: De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. doi: 10.1517/14728214.13.3.393 . Review. PubMed PMID: 18764719.
7: McGuigan C, Pathirana RN, Migliore M, Adak R, Luoni G, Jones AT, Díez-Torrubia A, Camarasa MJ, Velázquez S, Henson G, Verbeken E, Sienaert R, Naesens L, Snoeck R, Andrei G, Balzarini J. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother. 2007 Dec;60(6):1316-30. PubMed PMID: 17956908.
8: Jarvis CA, McGuigan C, Heard CM. In vitro delivery of novel, highly potent anti-varicella zoster virus nucleoside analogues to their target site in the skin. Pharm Res. 2004 Jun;21(6):914-9. PubMed PMID: 15212153.
9: De Clercq E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med Res Rev. 2003 May;23(3):253-74. Review. PubMed PMID: 12647310.
10: Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol. 2002 May;61(5):1140-5. PubMed PMID: 11961132.
